General Information of the Compound
Compound ID |
CP0257372
|
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Compound Name |
US10005783, 14
Show/Hide
|
||||||||||||||||||
Synonyms |
AKOS027338709
ARRY 470
ARRY-470
ARRY470
AS-35231
BDBM136597
CS-5722
GTPL8909
HY-12866
J3.628.138C
Larotrectinib
Larotrectinib [USAN:INN]
NYNZQNWKBKUAII-KBXCAEBGSA-N
PF9462I9HX
SCHEMBL2241012
UNII-PF9462I9HX
US8865698, 14
ZINC118399834
example 14 [US8865698 B2]
Show/Hide
|
||||||||||||||||||
Structure |
|
||||||||||||||||||
Formula |
C21H22F2N6O2
|
||||||||||||||||||
Molecular Weight |
428.443
|
||||||||||||||||||
Canonical SMILES |
O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F
Show/Hide
|
||||||||||||||||||
InChI |
InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1
Show/Hide
|
||||||||||||||||||
InChIKey |
NYNZQNWKBKUAII-KBXCAEBGSA-N
|
||||||||||||||||||
CAS |
1223403-58-4
|
||||||||||||||||||
Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
PubChem ID | |||||||||||||||||||
ChEMBL ID | |||||||||||||||||||
DrugBank ID |
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00934, High affinity nerve growth factor receptor
Cell-based Assay
Biochemical Assays
Clinical Information about the Compound
Drug 1 ( Larotrectinib )
Drug Name | Larotrectinib | ||
---|---|---|---|
Company | Loxo Oncology/Bayer | ||
Indication | |||
Target(s) |
Tropomyosin-related kinase A (TrkA)
Inhibitor
|